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Abstract
Aims: Antisense non-coding RNA in the INK4 locus (ANRIL) fixed genetic variants have consistently been linked
with coronary heart disease (CHD) risk. We investigated relationships between perinatal ANRIL promoter DNA
methylation and CHD risk markers in children aged 9 years. Genetic variants in the non-coding RNA ANRIL identify
it as an important CHD risk locus. Increasing evidence suggests that the early life environment may act through
epigenetic processes to influence later CHD risk markers such as increased arterial pulse wave velocity (PWV, a
measure of arterial stiffness) blood pressure or heart rate.
Methods and results: Using pyrosequencing, ANRIL DNA methylation at nine CpG sites was measured in the
umbilical cord from 144 children in a UK mother-offspring cohort and related to the descending aorta PWV
measured by velocity-encoded phase contrast MRI at age 9 years. Perinatal methylation was not associated with
child’s later blood pressure, but higher methylation at CpG5 was associated with increased childhood PWV (β = 0.
066 m/s/10 % methylation increase [95 % CI, 0.004 to 0.128], p = 0.037); 10 % decreases in methylation at CpG1 and
CpG2 were associated with increased heart rate (CpG1 β = 1.93 [0.07 to 3.8] beats/min, p = 0.041; CpG2 β = 2.30 [0.
18 to 4.41] beats/min, p = 0.033, accounting for potential confounding variables). The associations with perinatal
ANRIL promoter methylation were independent of neighbouring fixed genetic variants.
Conclusions: Our findings suggest developmental epigenetic regulation of ANRIL promoter methylation as a factor
in later CHD risk in children.
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Introduction
The 9p21 region is the strongest candidate for coronary
heart disease (CHD) risk at the population level identi-
fied so far from genetic studies [1, 2]. This region con-
tains several protein-coding genes that regulate cell cycle
progression (p14ARF, p15INK4b, p16INK4a) as well as
the long non-coding RNA antisense non-coding RNA in
the INK4 locus (ANRIL). Recent studies have shown
that genetic variants associated with CHD map onto the
ANRIL gene rather than the protein coding genes and
single-nucleotide polymorphisms (SNPs) in ANRIL,
linked to increased risk of CHD, are associated with de-
creased expression of ANRIL transcripts. [3–5] The
functional role of ANRIL in cardiovascular disease has
also been investigated in vascular smooth muscle, where
ANRIL knockdown altered the expression of genes in-
volved in the remodelling of the extracellular matrix,
suggesting that ANRIL impacts on CHD risk via the
modulation of these processes [6], leading to altered vas-
cular structure and function.
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Experimental and epidemiological studies provide strong
evidence that the early life environment influences later car-
diovascular disease risk [7], and this has been suggested to
involve the altered epigenetic regulation of gene function.
Epigenetic processes, which include DNA methylation, can
induce stable changes in gene expression without a change
in gene sequence [8]. However, to date, there have been no
longitudinal studies showing that prenatal epigenetic pro-
cesses are associated with CHD risk. Thus, the aim of this
study was to examine the relationship between DNA
methylation levels at birth in the promoter region of ANRIL
with blood pressure (BP), heart rate (HR) and pulse wave
velocity (PWV) in children aged 9 years. Increased resting
HR is a risk factor for CHD in males and is associated with
cardiovascular death in both sexes [9–12], while increased
PWV, an indicator of arterial stiffness, has been shown to
be a strong predictor of atherosclerosis, cardiovascular mor-
tality, myocardial infarction, angina, heart failure, and stroke
in adulthood [13, 14]. Here, we found that ANRIL promoter
methylation at birth was associated with both heart rate and
arterial stiffness at 9 years of age, providing further evidence
for the importance of the early life environment in influen-
cing health in later life and suggesting that differential
methylation of CpG loci within the promoter of ANRIL
may provide a marker to identify individuals in early life at
increased risk of CHD disease in later life.
Methods
Cohort
In a UK mother-offspring study (Southampton Women’s
Survey, SWS [15]), maternal characteristics were ascer-
tained before and during pregnancy and offspring mea-
surements obtained after birth.
Child adiposity measurement
At age 8 years, child adiposity measurements were made by
dual-energy X-ray absorptiometry (Hologic Discovery,
paediatric scan mode, Hologic Inc., Bedford, MA) [16]. The
instrument was calibrated daily; coefficients of variation
were 1.4 to 1.9 %. Follow-up of the children and sample
collection/analysis was carried out under Institutional
Review Board approval (Southampton and SW Hampshire
Research Ethics Committee) with written informed con-
sent. Clinical investigations were conducted according to
the principles expressed in the Declaration of Helsinki.
Pulse wave velocity measurements
At age 9 years, a subset of SWS participants was invited to
attend for magnetic resonance imaging (MRI) assessment
of cardiovascular structure and function. PWV was mea-
sured in the descending aorta. A phase-contrast flow-
mapping sequence was acquired at the level of the pulmon-
ary trunk in the proximal descending aorta and in the distal
descending aorta above the bifurcation. A velocity-encoding
gradient was applied in the through-plane direction. Right
brachial blood pressure was measured immediately follow-
ing the acquisition. Velocity flow curves were generated
using open source software (Osirix). Descending aortic
PWV was calculated using Matlab software (Mathworks,
Natick, MA) and the transit time method [17] from dis-
tance between the flow acquisitions/transit time of the sys-
tolic wave front between the two flow acquisition sites.
DNA methylation analysis
Genomic DNA was extracted from umbilical cord tissue
which had been collected at birth and stored at −80 °C.
DNA was bisulphite converted using the EZ DNA methyla-
tion kit (ZymoResearch, USA) (Primers: Additional file 1:
Table S2). Modified DNA was amplified using Hotstart Plus
DNA polymerase (QIAGEN). PCR products were immobi-
lised on streptavidin–sepharose beads (GE Healthcare),
washed, denatured and released into annealing buffer
containing sequencing primer. Pyrosequencing was carried
out on a Pyromark MD (Qiagen). %methylation was calcu-
lated using the Pyro Q CpG software (QIAGEN). Add-
itional file 2: Table S1 shows CpG genomic co-ordinates.
Statistics
Statistical analysis was performed using Stata (Statacorp,
USA) versions 13.1 and 14.0. Descending aorta pulse
wave velocity, heart rate, and systolic and diastolic blood
pressures at 9 years were used as outcome measures.
%methylation of ANRIL CpGs 1-9 were used individu-
ally as predictors, together with sex and age at MRI scan.
All outcomes measures were approximately normally
distributed. Linear regression models were built for each
outcome with ANRIL methylation (taking one CpG at a
time) as a predictor, adjusting for sex and age at MRI
scan. Where regression residuals showed heteroscedasti-
city (Cook-Weisberg test [18]), robust estimators of
standard errors were calculated and used for calculating
the test statistic. If CpGs were significant predictors of
outcomes (p < 0.05), further adjustments were made for
child’s fat mass (or fat %) at age 9 years and maternal
smoking during pregnancy. Results are presented as re-
gression coefficients multiplied by 10 (β), representing
the change in cardiovascular outcome per 10 % change
in methylation, with associated p values and 95 % confi-
dence intervals. DNA Methylation levels of some CpGs
were highly correlated (Additional file 3 : Table S3, CpGs
1-3 and 5-7), and it was therefore inappropriate to carry
out statistical corrections that assume independence,
such as Bonferroni or Benjamini-Hochberg correction.
Results
Cohort characteristics
We studied 144 children (72 boys) (Table 1); mean heart
rate was 80.2 bpm; mean descending aorta PWV was
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3.4 m/s (within previously reported childhood ranges
[19]); mean % and total fat mass measurements were
24.6 % and 4.8 kg, respectively; 14.7 % of mothers
smoked during pregnancy. Umbilical cord ANRIL
methylation levels varied greatly; for example, the 5th–
95th percentile ranges for CpGs 2, 3 and 5 were 20–
30 % (Additional file 2: Table S1).
Heart rate is associated with ANRIL promoter DNA
methylation
To examine whether DNA methylation levels within
the promoter region of ANRIL were associated with
heart rate, we analysed the methylation status of nine
CpG sites within the promoter of ANRIL at birth in
relation to measures of cardiovascular risk at age
9 years. Methylation at CpG1 and CpG2 correlated
inversely with heart rate (p = 0.031, p = 0.02, respect-
ively) (Table 2, Fig. 1). These associations remained
significant in multivariate models that controlled for
child’s total fat mass at 8 years, sex, age and maternal
smoking; CpG1 p = 0.041, CpG2 p = 0.033. The total
variances in heart rate explained were 7.6 and 8.6 %
for CpG1 and CpG2, respectively.
PWV associates with DNA methylation at the ANRIL
promoter
ANRIL promoter CpG5 methylation was positively asso-
ciated with PWV (p = 0.037) (Fig. 2, Table 3); the
association remained after controlling for child’s
total fat at 8 years, sex, age and maternal smoking;
adjusted p = 0.026 (total variance explained 3.2 %).
Childhood total fat and %fat at 8 years and maternal
smoking were not independent predictors of PWV.
Blood pressure is not associated with ANRIL DNA
methylation
ANRIL methylation showed no association with child-
hood systolic or diastolic blood pressure.
MatInspector was used to examine the DNA sequence
surrounding CpGs1, 2 and 5 to determine if these CpG
dinucleotides aligned with any known transcription
factor (TF) binding sites. This identified ten different
potential TFs with a core similarity score >0.8, including
SMAD, PPAR, ERE, KLF, HIF and GATA (Additional
file 4: Figure S1).
All the associations with perinatal ANRIL promoter
methylation were independent of neighbouring genetic
variants (data not shown).
Discussion
Lower DNA methylation at two adjacent CpG dinucleo-
tides within the promoter of ANRIL was associated with
faster heart rate, independent of potential confounders.
Elevated heart rate is an independent risk factor for
CHD [20, 21], a predictor of cardiovascular mortality
[22], and is associated with reduced longevity, even in
those without pre-existing cardiovascular conditions
[22]. Mean resting pulse rate has increased by up to
2 bpm among 9–11-year UK children over nearly
30 years [23]. This has been attributed to an increase in
adiposity and decline in physical fitness among children;
however, these findings suggest that the prenatal envir-
onment may also be an important determinant of later
CHD risk and provides support for epigenetic processes
Table 1 Characteristics of the study population
Number Percent or median (25th, 75th
percentile)
Mother
Pregnancy smoking
status
143
Smoker 21 14.7 %
Non-smoker 122 85.3 %
Infant
Birth weight, kg 142 3.4 (3.1–3.8)
Sex 144
Male 72 50 %
Female 72 50 %
%fat age 8 years 132 24.6 (20.5–29.6)
Total fat mass age
8 years, kg
132 6.6 (5.0–09.0)
Child follow-up
Age, year 144 9.4 (9.3–9.6)
Heart rate, bpm 137 80.2 (74.0–85.4)
Systolic BP, mm Hg 135 98.0 (92.0–105.0)
Diastolic BP, mm Hg 135 58.0 (55.0–62.0)
Descending aorta PWV,
m/s
137 3.4 (3.2–3.7)
Table 2 Heart rate (bpm) at age 9 years in relation to ANRIL
promoter DNA methylation
CpG Hg19 coordinates β value p value Adjusted p
1 chr9: 21993721 −1.98 0.031 0.041
2 chr9: 21993697 −2.45 0.020 0.033
3 chr9: 21993694 −2.56 0.080 0.103
4 chr9: 21993654 −1.5 0.195 0.168
5 chr9: 21993645 −0.669 0.484 0.488
6 chr9: 21993638 −1.42 0.128 0.196
7 chr9: 21993629 0.096 0.938 0.936
8 chr9: 21993603 −1.18 0.288 0.402
9 chr9: 21993583 −0.626 0.642 0.463
β values represent a 10 % change in methylation. DNA methylation levels
were determined via pyrosequencing. Linear regressions were used to
compare methylation and heart rate. Adjusted p values are adjusted for age,
sex, total fat mass at 8 years and mother smoking during pregnancy
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Fig. 1 Heart rate (bpm) vs ANRIL DNA methylation at CpG1 and CpG2. DNA methylation levels were determined via pyrosequencing. The x-axis
shows quartiles of methylation; values are means + SEM. N = 132
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in mediating the long-term consequences of the prenatal
environment on CHD risk.
Higher DNA methylation at CpG5, which lies more distal
to the transcriptional start site (TSS) of ANRIL, was associ-
ated with higher PWV—a marker for increased arterial
stiffness that also indicates greater cardiovascular risk. This
difference in the direction of associations observed between
the methylation of the individual CpG sites within the
ANRIL promoter and CHD risk factors may reflect the fact
that gene promoter DNA methylation often influences ex-
pression through the modulation of transcription factor
binding [24], and while some studies have shown that the
methylation status of CpG sites can be closely aligned to
that of their neighbours, especially within a CpG island, de-
velopmentally induced changes are often CpG site specific
[25]. Consistent with this, an in silico analysis predicted that
distinct transcription factors may bind across the different
CpG loci associated with heart rate and PWV, respectively,
suggesting that the CpG sites may be independently regu-
lated. Across CpGs 1 and 2, potential TF binding sites
include SMAD and KLF, which are involved in heart devel-
opment and the proliferation of cardiomyocytes [26–28], as
well as PPAR, linked to atherosclerosis [29] and ERE, which
is important for angiogenesis and modulation of vascular
smooth muscle cells (VSMC) [30]. CpG 5 is close to a po-
tential TF binding site for HIF—an important regulator of
oxygen homeostasis [31], as well as a binding site for
GATA, which is critical for heart development [32]. While
transcription factor binding will need to be validated ex-
perimentally, this does suggest distinct roles for CpG 1 and
2 compared to CpG5 and is compatible with the purported
role of ANRIL transcripts in VSMC [6].
The strengths of this study are the relative large number
of participants with detailed phenotypic cardiovascular
characterisation. There are some limitations; this is only a
preliminary study, and the results need to be replicated in
other studies to confirm our findings. Secondly, we ana-
lysed methylation in umbilical cord samples, and DNA
methylation patterns are often tissue-specific; however,
the umbilical cord does contain a high proportion of fetal
vascular tissue, and so is likely to be relevant to cardiovas-
cular disease risk phenotypes studied here. A third limita-
tion is that although all known SNPs within 45 bp of the
CpGs sites studied were excluded by direct sequencing,
without genome-wide sequencing, it is not possible to ex-
clude the effect of distant SNPs. Fourth, we did not have
longitudinal data, so cannot ascertain whether methyla-
tion of ANRIL is a driver of altered heart rate or PWV or
a consequence of these changes. It would be interesting to
follow the methylation of ANRIL with regard to CHD risk
factors during childhood and later life to determine how
ANRIL methylation tracks with these factors over time,
and it would also be interesting to examine ANRIL ex-
pression levels. Nevertheless, the finding that altered
methylation of CpGs within the promoter of ANRIL, a
long non-coding RNA previously linked to CHD risk
through GWAS, is associated with predictors of CHD risk
in childhood suggest that differential methylation of this
region maybe a marker which could be used to identify
those individuals at increased risk of CHD in early life.
Conclusion
In summary, our findings suggest that altered epigenetic
regulation of ANRIL, a gene strongly linked to CHD by
genome-wide association studies, is associated with al-
terations in both heart rate and arterial stiffness. Cardio-
vascular disease is often identified late in its pre-clinical
phase, necessitating intervention to manage disease pro-
gression. Thus, the identification of perinatal epigenetic
marks that are predictive of later disease risk represents
an opportunity to identify those individuals who are at
greater risk of subsequent disease in early life and a
means to monitor the effectiveness of preventative
interventions.
Additional files
Additional file 1: Table S2. Primers used for methylation analysis of
ANRIL promoter. (DOCX 13 kb)
Additional file 2: Table S1. Observed DNA methylation ranges for CpG
dinucleotides quantified by pyrosequencing. CpG coordinates are
provided in Hg19. Distance from transcriptional start site (TSS) in base
pairs. N = 132. (DOCX 14 kb)
Additional file 3: Table S3. Correlation of the methylation levels
between CpG sites. Pairwise Spearman correlation. (DOCX 15 kb)
Additional file 4: Figure S1. Predicted consensus transcription factor
binding sequences. MatInspector was used to examine the DNA
sequence around CpGs 1, 2, and 5 to identify potential binding sites for
transcription factors using MatInspectors core/vertebrate transcription
factor database. Core sim. (core similarities) and Matrix sim. (matrix
similarities) are scored out of 1. Results with Core Sim. scores >0.8 are
shown. Core sim. Refers to base pair matching for the core consensus
Table 3 Pulse wave velocity (m/s) at age 9 years in relation to
ANRIL DNA methylation
CpG Hg19 coordinates β value p value Adjusted p
1 chr9: 21993721 0.0089 0.803 0.770
2 chr9: 21993697 0.0173 0.622 0.592
3 chr9: 21993694 −0.053 0.357 0.723
4 chr9: 21993654 0.0016 0.967 0.621
5 chr9: 21993645 0.0663 0.037 0.026
6 chr9: 21993638 0.0207 0.583 0.345
7 chr9: 21993629 0.0154 0.736 0.659
8 chr9: 21993603 0.0258 0.531 0.322
9 chr9: 21993583 0.0828 0.176 0.087
β values represent a 10 % change in methylation. DNA methylation levels
were determined via pyrosequencing. Linear regressions were used to
compare methylation and pulse wave velocity. Adjusted p values are adjusted
for age, sex, total fat mass at 8 years and mother smoking during pregnancy
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sequence (underlined + BOLD in transcription factor sequences) while
Matrix sim. Refers to overall matching across the full binding site.
(DOCX 17 kb)
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